Today: 29 April 2026
Browse Category

NASDAQ:AMGN 4 November 2025 - 21 December 2025

Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen shares last traded near $327.38 as investors weighed a new FDA label expansion and U.S. drug-pricing deals announced Dec. 19. The NYSE will close early Dec. 24 and remain shut Dec. 25, thinning liquidity and increasing volatility risk. Amgen, a Dow component, remains sensitive to policy headlines and year-end positioning.
21 December 2025
···
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Amgen traded near $343 Thursday, close to record highs after a year of strong earnings and FDA approval for its lung-cancer drug Imdelltra. Shares are up about 34% year-to-date, outpacing the broader market. Trefis set a bullish $450 target, citing 12% revenue growth and $13 billion in free cash flow. EverSource Wealth Advisors cut its Amgen stake by nearly 28% in Q2.
4 December 2025
··
Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally

Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally

Amgen shares closed at $345.42 on December 3, 2025, up 2% and setting a new 52-week high near $345.95. The stock has gained about 35% year-to-date and over 25% in the past year. Amgen beat Q3 earnings forecasts and raised full-year guidance, but analysts’ 12-month targets mostly remain below current prices. The consensus rating ranges from “Hold” to “Moderate Buy.”
3 December 2025
··
Amgen (AMGN) Stock Today: Earnings Momentum, Obesity Breakthroughs and Fresh December 2, 2025 Forecasts

Amgen (AMGN) Stock Today: Earnings Momentum, Obesity Breakthroughs and Fresh December 2, 2025 Forecasts

Amgen shares traded at $338.67 on December 2, 2025, up 0.35% and near 52-week highs after strong Q3 results and a raised 2025 outlook. Several institutional investors disclosed reduced AMGN holdings in Q2 filings. Technical analysts flagged a short-term bullish setup. The company’s obesity and cardiovascular drugs remain key pipeline drivers.
2 December 2025
···
Nasdaq Stumbles as Fed Jitters Mount, Intel Soars, Tariffs Rattle Tech Markets

AI Rally Hits Speed Bump as Futures Fall – Key Facts Before the Nov. 4 Market Open

U.S. stock futures fell sharply early Tuesday, with Nasdaq 100 futures down 1.2% and S&P 500 off 0.9%. The drop follows a stalled tech rally and overnight losses in Europe and Asia. Key economic data releases are delayed by a government shutdown, adding to market uncertainty. Palantir shares slid over 4% despite strong earnings, while Bitcoin dropped 3% to around $104,000.
4 November 2025
···········
1 2

Stock Market Today

  • Growing Trend of Americans Using Apps for Copycat Investing
    April 28, 2026, 9:03 PM EDT. More Americans are opting for apps that automatically replicate trades from high-profile investors, a practice known as copycat investing. This trend emerges amid volatile stock markets, attracting users seeking straightforward investment strategies. Expert Evyn Moon highlights benefits like learning from experienced traders and potential downsides including lack of personal control and risk exposure. The rise reflects changing investor behavior driven by technology and market unpredictability.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop